Researchers found that roughly 30% of chlamydia and gonorrhea patients did not receive treatment, while only 14% and 39% received recommended antibiotics.
Researchers find a marked increase in tetracycline-resistant gonorrhea and increased colonization with tetracycline-resistant Staphylococcus aureus following the rollout of doxyPEP.
Among patients prescribed doxycycline post-exposure prophylaxis, cases of syphilis, chlamydia, and gonorrhea fell by 86.4%. 89.7%, and 54.7%, respectively.
The rate of gonorrhea cases across Europe rose by 31% in 2023 compared with 2022, and is up 321% since 2014.
Two studies in California found significant reductions in chlamydia and syphilis in the year after doxycycline post-exposure prophylaxis guidelines were released.
The number of STIs declined almost 2% from 2022 to 2023, a sign that the dramatic rise in STIs since 2011 might be leveling off.
Health officials say the STI epidemic is at a tipping point, with more federal support needed for testing and treatment.
The FDA said the test offers a private and quick testing option, along with streamlined treatment, if needed.
Guidelines published yesterday by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) contain three new recommendations for treating adults who have Clostridioides difficile infection (CDI).
A modeling study that incorporated air movement patterns from farms affected early in the highly pathogenic H5N2 avian influenza outbreak that hit US poultry in 2015 suggests that most affected farms in Iowa may have received airborne virus from farms within and outside the state.
